Structure via PubChem · Public domain (PubChem)
D-dopa
Sign in to saveAlso known as dopa D-form, (+)-3-(3,4-dihydroxyphenyl)alanine, (+)-3,4-dihydroxyphenylalanine, D-3-(3,4-dihydroxyphenyl)alanine, D-3,4-dihydroxyphenylalanine, 3-hydroxy-D-tyrosine, 3,4-dihydroxy-D-phenylalanine
-DOPA dextrodopa) is similar to (levodopa), but with opposite chirality. Levo- and dextro- rotation refer to a molecule's ability to rotate planes of polarized light in one or the other direction. Whereas is moderately effective in the treatment of Parkinson's disease (PD) and dopamine-responsive dystonia (DRD) by stimulating the production of dopamine in the brain, is biologically inactive.
In the Vinony graph
Vinony's link graph records 1,389 inbound references to D-dopa, and connects out to optical rotation, biology and medication.
It is catalogued under topics including Alpha-Amino acids, Aromatic amino acids and Catecholamines.
Vinony links it to 9 Wikipedia language editions.
Chemical data
- Formula
- C9H11NO4
- Molecular weight
- 197.19 g/mol
- IUPAC name
- (2R)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
- SMILES
- C1=CC(=C(C=C1C[C@H](C(=O)O)N)O)O
- InChIKey
- WTDRDQBEARUVNC-ZCFIWIBFSA-N
- XLogP
- -2.7
- Polar surface area
- 104 Ų
- H-bond donors
- 4
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Mass
- 197.068808
Show 5 more facts
- stereoisomer of
- levodopa
- chemical formula
- C₉H₁₁NO₄
- found in taxon
- Portulaca grandiflora
- isomeric SMILES
- C1=CC(=C(C=C1C[C@H](C(=O)O)N)O)O
- canonical SMILES
- C1=CC(=C(C=C1CC(C(=O)O)N)O)O
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
-DOPA dextrodopa) is similar to (levodopa), but with opposite chirality. Levo- and dextro- rotation refer to a molecule's ability to rotate planes of polarized light in one or the other direction. Whereas is moderately effective in the treatment of Parkinson's disease (PD) and dopamine-responsive dystonia (DRD) by stimulating the production of dopamine in the brain, is biologically inactive.
Avoiding unwanted production of D-DOPA is a goal for commercial synthesis of -based drugs to treat Parkinson's disease.
Excerpted from Wikipedia’s “D-dopa” article, available under the CC BY-SA 4.0 licence.